|| Checking for direct PDF access through Ovid
The aim of this study (SITEPO™) is to evaluate the influence of the intravenous injection site (drip chamber injection site, venous injection site or venous fistula needle) on plasma concentration of epoetin β (Neorecormon®, Roche), a recombinant Human Erythropoietin (rHuEPO), at the end of in vitro hemodialysis sessions. No practical administration guidelines are available.Twenty 1-h dialysis sessions are performed. Before each dialysis, the circuit is filled with 270 ml, of heparinized total human blood whose hematocrit is adjusted to 35%. A common dosage of epoetin β in clinical practice (3000 IU) is studied for the three injection sites and for reference experiments in which rHuEPO is not injected into the dialysis circuit. Plasma concentrations of erythropoietin are measured by ELISA. The physiologically endogenous erythropoietin concentration is systematically determined and removed from the total epoetin β concentration.Average epoetin β plasma levels returned are not significantly different between the three injection sites and no significant rHuEPO loss is observed after injection into the drip chamber, the venous injection site and the venous fistula needle compared with reference experiments.The three intravenous injection sites of rHuEPO can be used at the end of dialysis without significant epoetin β loss.